Nelly ZIADE 🍀 Nellziade
5 years 4 months ago
Guselkumab in patients with active #Psoriatic_Arthritis & who failed anti-TNF: COSMOS study Phase 3b
A new option for the difficult-to-treat patients with PsA
@DrLauraCoates
#EULAR2021 https://t.co/2aOqZYfbsT
Nelly ZIADE 🍀 Nellziade
5 years 4 months ago
Upacitinib in #Psoriatic_Arthritis with axial manifestations
Post hoc analysis from SELECT PsA1/2
#EULAR2021
@deodhara https://t.co/867c2J3DiI
The second day of EULAR 2021 took a big leap in online content. #EULAR2021 generated 2500 tweets yesterday. Here is a compilation (with links) of presentations were the “Best” as seen by our RheumNow faculty.
The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021. The goal (as per 2009 recommendations) was “To develop recommendations, based upon the best scientific evidence, for the optimal treatment of patients with PsA” Dr.
On day 2 of EULAR conference, Dr. Michael Ehrenstein presented OP0129, a presentation on the BEAT-LUPUS trial looking at belimumab therapy after rituximab. B cell depletion with rituximab is common treatment for refractory SLE, though real-world data for rituximab has been uncertain. It is known that B-cell activating factor (BAFF) levels can increase after rituximab, which can lead to disease flares. Using belimumab, a human monoclonal antibody
EMEUNET EMEUNET
5 years 4 months ago
Very interesting 🤔 talk about the role of #comorbidities in difficult to treat #RA by our fabulous #emeunet past chair @ElenaNikiUK at #EULAR2021 @eular_org https://t.co/zyQ0DkKhbu
The Lancet Rheumatology TheLancetRheum
5 years 4 months ago
NEW RESEARCH—Safety and efficacy of #rituximab in #SystemicSclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial https://t.co/Sb3d1kPhL4 #LancetRheumatology https://t.co/4SMVGY0C3M
Md Yuzaiful Md Yusof Yuz6Yusof
5 years 4 months ago
Potential new player on the block, B-cell associated cytokine IL-40 in #Sjogren. Dr Rizzo showed ⬆️IL40 expression in salivary gland biopsy & bloods in pSS and pSS-associated lymphoma. Future work will clarify the exact role of IL-40 as a tx target #EULAR2021 #POS0177 @RheumNow https://t.co/uXAYAlkdtD
Meral K. El Ramahi, MD MeralElRamahiMD
5 years 4 months ago
⭐️Deucravacitnib = oral TYK2i w/ downstream inhibitory effects on IL23, IL12 & type I IFN pathways ⭐️Recent studies (POETYK PSO-1/2) show that it outperforms Otezla per PASI75 ⭐️OP0227 shows it is also efficacious for active PsA vs PBO w/ no serious AEs #EULAR2021 @Rheumnow https://t.co/qA1NsLzQsF
Md Yuzaiful Md Yusof Yuz6Yusof
5 years 4 months ago
Does #baricitinib affect B-cell activity in #SLE?Dr Dorner reported in patients with dsDNA ab+ve (=>30iU/mL), Bari 4mg reduced dsDNA,anti-Sm, cardiolipin and IgG at Wk24 vs placebo. In pts who dsDNA normalised, their SRI-4 was no different vs dsDNA+ #EULAR2021 #POS0686 @RheumNow https://t.co/pmNWEE9hqg
Meral K. El Ramahi, MD MeralElRamahiMD
5 years 4 months ago
OP0227: Efficacy of Deucravactinib for PsA?
⭐️Deucrav = TYK2i.
⭐️Dr. Mease et al show MDA by wk16 + stat. signif improv in ACR20/50/70, enthes, & dactyl w/ deucrav vs PBO in pts w/ active PsA.
⭐️Incl crit: failed at least 1 csDMARD/NSAID/GC & up to 1 TNFi
#EULAR2021 @Rheumnow https://t.co/1jjsZIODFV
Md Yuzaiful Md Yusof Yuz6Yusof
5 years 4 months ago
#SLE and #Sjogren: is there a path for these to converge? Dr Martin-Guttierez used #MachineLearning to analyse blood & identified 2 endotypes. Both had different trajectory in disease activity & damage. May be useful to stratify appropriate therapy #EULAR2021 #POS0174 @RheumNow https://t.co/R4NMDJYVbY
Janet Pope Janetbirdope
5 years 4 months ago
Better pics re JAKi retention better than bDMARDs in RA. But single site, ? Selection bias. Curves spread after 1st yr of Rx. Findings same if only 1st line adv Rx or adjusted for line of therapy POS0205 #EULAR2021 @RheumNow https://t.co/6HYpgVeyiw https://t.co/5mjpUFfWoG
Richard Conway RichardPAConway
5 years 4 months ago
Dr Eder reports population-based, matched cohort study 3 million people. IMID associated ⬆️ hospitalisation in COVID-19. OR 1.23, 95% CI 1.10, 1.37 @RheumNow #EULAR2021 Abstr#OP0285 https://t.co/KDK5j1Gg0X
Dr. Rachel Tate uptoTate
5 years 4 months ago
Dr. Laura Coates discusses "what is fatigue" based on clinical outcome and disease activity measures in PsA. Three main groups stood out in predicting fatigue in these patients: level of inflammation, chronic pain, and chronicity of PsA disease. #EULAR2021 @RheumNow https://t.co/pFYRb1X7pT
